The Food and Drug Administration (FDA) has approved Imjudo (tremelimumab-actl) in combination with durvalumab for the treatment of adults with unresectable hepatocellular carcinoma (HCC). Imjudo is a human monoclonal antibody that targets the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The novel dose and schedule of the combination (the STRIDE regimen [Single Tremelimumab Regular Interval…
Clear management guidelines are needed for AKI during immune checkpoint inhibitor therapy, according to investigators.
Alymsys is a vascular endothelial growth factor inhibitor.
Vegzelma is a vascular endothelial growth factor inhibitor.
PFS improved with cabozantinib + nivolumab + ipilimumab for patients with previously untreated advanced renal cell carcinoma
Trial did not meet primary efficacy end point of disease-free survival in patients with localized RCC at high risk for postnephrectomy relapse
Among patients with a variety of solid tumors, investigators found favorable associations of immune checkpoint inhibitor therapy with quality of life compared with no immunotherapy use.
The CheckMate -914 trial included patients with localized RCC who underwent radical or partial nephrectomy and who were at high risk of relapse.
Strategies, such as booster doses, appear warranted in this population.
